HC-030031, TRPA1 blocker

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

TRPA1 also known as the transient receptor potential ankyrin 1 is a non-selective cation channel with a mass of approximately 128 kDa. This protein is widely expressed in sensory neurons especially in dorsal root ganglia and trigeminal ganglia. TRPA1 is known for its activation by various physical and chemical stimuli including temperature mechanical forces and naturally occurring compounds like allicin found in garlic and allyl isothiocyanate from mustard oil. Compounds like diallyl trisulfide diallyl disulfide and polygodial have also been reported to activate TRPA1 and it plays a role in the perception of pain.

Biological function summary

TRPA1 contributes significantly to the sensation of pain and irritation. Functioning as a part of a receptor complex on the cellular membrane it integrates environmental stimuli to trigger responses such as pain and inflammation. TRPA1 interacts with various ligands which can modulate its activity leading to the perception of noxious cold and harsh chemical conditions. Recent studies also revealed its involvement in bronchial conditions implicating compounds like eucalyptol and related derivatives in modulating its effects.

Pathways

TRPA1 interacts with several critical sensory pathways involved in pain and thermosensation. It is an important player within the neurogenic inflammation pathway and the nociceptive pathway. In these pathways TRPA1 often acts together with related proteins like TRPV1 further modulating the response to heat and capsaicin. These interactions suggest a complex interplay between different TRP channels influencing how organisms react to different harmful stimuli.

TRPA1 is associated with inflammatory pain conditions and respiratory diseases like asthma. The regulation of TRPA1 activity can influence the progression of these conditions offering potential therapeutic targets. Its connection to TRPV1 in these diseases highlights the synergy between these receptors in managing pain and inflammation. Therefore targeting TRPA1 and its related proteins could help develop treatments aimed at alleviating symptoms linked to these disorders.